Business
Publication - Annual Report & Financial Statements
EDX Medical Group PLC published its Annual Report and Financial Statements for the year ending March 31, 2025, reporting revenue of £0.1 million and a loss of £3.6 million. The loss was higher than expected due to increased product development and a £200,000 provision for non-recurring items, partially offset by £0.5 million in finance income. Key highlights include the development of a new AI-powered prostate cancer diagnostic test, a March 2025 equity fundraising of £3 million at 14p per share, expansion of European partnerships, and a Master Service Agreement with Royal Marsden NHS Foundation Trust. Disclaimer*
About this update from Edx Medical Group Plc
[{"type":"text","content":"\n\nThis announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.\n \n \n\n \n22 August 2025\nEDX Medical Group plc · EDX\nAQSE: EDX\n(\"EDX Medical\" or the \"Company\")\n \nPublication of Annual Report and Financial Statements\n \nCAMBRIDGE, UK: EDX Medical Group, which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, has today published its Annual Report and Financial Statements for the year ending March 31, 2025.\nHighlights:\n· Development of a new 'super test' for prostate cancer, a breakthrough diagnostic tool incorporating Artificial Intelligence (AI) and multiple biomarkers.\n· Equity fundraising in March 2025 raising £3 million through the placing of shares at 14p per share.\n· Expansion of European partnerships.\n· A Master Service agreement with Royal Marsden NHS Foundation Trust.\nRevenue for the year was £0.1 million, reflecting the commencement of new partnerships during this transitional year. The loss for the year was £3.6 million, with costs somewhat higher than expected due to additional product development activities and approximately £200,000 provision for non-recurring items, partly offset by £0.5 million of finance income.\nJason Holt, chairman, EDX Medical, commented: \"The Group has continued to strengthen its position as an emerging leader in the field of medical diagnostics enabling me to report on our progress across multiple facets of the business including development and launch of new cancer tests, signing partnership agreements with key hospital groups and completing a successful fund raise which will further support the key strategies driving our growth and innovation in the years ahead.\n\"The Group has embarked on developing several key products that have received strong market awareness. I am pleased to report that we announced the development of a new super test for prost...